Table of Contents
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Study
1.4 Stakeholders
2 Research Methodology
2.1 Market Size Estimation
2.2 Market Crackdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data Points Taken From Secondary Sources
2.3.2 Key Data Points Taken From Primary Sources
2.4 Assumptions
3 Executive Summary
4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
6 Migraine Drugs Market, By Product Type
6.1 Introduction
6.2 Acute Migraine Treatment
6.2.1 Analgesic
6.2.2 Ergotamine
6.2.3 Triptans
6.3 Preventive Migraine Treatment
6.3.1 Beta Blockers
6.3.2 Anti-Serotonergic Drugs
6.3.3 Antidepressants
6.3.4 Anti-Convulsants
6.3.5 Calcium Channel Blockers
6.3.6 Others
7 Migraine Drugs Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Injection
7.4 Others
9 Migraine Drugs Market, By End User
9.1 Introduction
9.2 Hospitals Based Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
10 Migraine Drugs Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Rest of Europe (RoE)
10.4 Asia Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 Rest of Asia Pacific
10.5 Rest of the World (RoW)
11 Competitive Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
12 Company Profiles*
12.1 Introduction
12.2 Abbott Labrotatories
12.3 Allergan
12.4 Amgen
12.5 Glaxosmithkline
12.6 Pfizer.
12.7 Eli Lilly
12.8 Aegis Therapeutics, LLC.
12.9 Johnson & Johnson
12.10 Astrazeneca PLC
Note: *Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.
* 10 to 15 Market Leaders Will Be Profiled
* Segmentation May Change During the Planned Research Work
North America dominates the migraine drugs market with the North America accounted major market share in 2017. Established healthcare infrastructure; and increasing demand for preventive migraine treatment options are some of the major driving factors driving the growth of this market in North America. The Asian migraine drugs market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about novel treatments among people in the region. The rising focus of prominent players on the Asian migraine drugs market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the migraine drug manufacturers.
Prominent players in the suture anchor devices market Abbott Laboratories (U.S.), Allergan (Ireland), Amgen (U.S.), GlaxoSmithKline (UK), Pfizer (U.S.), Eli Lilly (U.S.), Aegis Therapeutics, LLC. (U.S.), Johnson and Johnson (U.S.), and AstraZeneca PLC. (UK).
This research report covers the global Migraine Drugs market by method; product type; route of administration; end user; and geography.
Growth opportunities and latent adjacency in Migraine Drugs Market